Placing New MPN Therapies into Context Through Illustrated Case Discussions


Advances in the understanding of the pathogenesis of the myeloproliferative neoplasms (MPNs), polycythemia vera (PV) and primary myelofibrosis (MF), have led to improved treatment interventions. Approximately 95% of patients with PV and 50% of patients with MF have mutations in Janus kinase 2 (JAK2), which is essential for the normal development of granulocytes, erythrocytes, and platelets. Other less common shared mutations include CALR (calreticulin mutation) and MPL (myeloproliferative leukemia virus oncogene). Identification of mechanisms that cooperate with JAK-STAT signaling to predict disease progression and rationally guide the development of novel therapies is paramount to improving outcomes for patients.

June 5, 2022 | Hilton Chicago, IL 

Read More

Next Post

Whole Person Care: How Do We Get There?

To mark Mental Health Awareness Month, our Director of Behavioral Health Specialty Solutions, Melissa Giampietri, joins the NextGen Advisors to spotlight the opportunities and challenges of integrating mental/behavioral health with physical care services.
Featured Video Play Icon